Scoop has an Ethical Paywall
Living Cell Technologies - Latest News [Page 1]
LCT files pericyte protective agent provisional patent
Tuesday, 7 November 2017, 4:14 pm | Living Cell Technologies
7 November 2017 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has filed a provisional patent for pericyte protective agents titled “PERICYTE PROTECTIVE AGENTS FOR NEUROLOGICAL DISORDERS INCLUDING NEURODEGENERATIVE ... More >>
Collaboration to extend product pipeline
Tuesday, 16 May 2017, 1:31 pm | Living Cell Technologies
16 May 2017 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has initiated a research collaboration with the Centre for Brain Research (CBR) at the University of Auckland. The research collaboration will explore how ... More >>
Treatment completed for all patients in Parkinson’s trial
Monday, 1 May 2017, 11:23 am | Living Cell Technologies
1 May 2017 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has completed treatment of all six patients in the third and final group of patients in the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, ... More >>
Group 2 Parkinson’s trial patients’ treatment completed
Thursday, 22 December 2016, 2:57 pm | Living Cell Technologies
22 December 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has completed treatment of all six patients in group 2 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City ... More >>
Group 1 patients successfully treated in Parkinson’s trial
Wednesday, 5 October 2016, 1:23 pm | Living Cell Technologies
5 October 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has completed treatment of all six patients in group 1 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City ... More >>
Clinical trial of NTCELL for Parkinson’s disease
Thursday, 24 March 2016, 1:07 pm | Living Cell Technologies
24 March 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. More >>
LCT completes $2.8m private placement and announces SPP
Wednesday, 17 February 2016, 12:19 pm | Living Cell Technologies
17 February 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has completed the placement of 54,607,546 shares at $0.05063 to wholesale investors resident in New Zealand, raising $2,764,621. The issue price ... More >>
LCT receives ethics approval for Phase IIb Parkinson’s trial
Wednesday, 3 February 2016, 4:47 pm | Living Cell Technologies
3 February 2016 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies has received approval from the Northern A Health and Disability Ethics Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. ... More >>
NTCELL® Continues to Reverse the Progression of Parkinson’s
Wednesday, 27 January 2016, 1:05 pm | Living Cell Technologies
27 January 2016 – Sydney, Australia & Auckland, New Zealand – Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and ... More >>
NTCELL® Clinical Study in Parkinson’s Meets Endpoints
Monday, 15 June 2015, 12:09 pm | Living Cell Technologies
NTCELL® Clinical Study in Parkinson’s Meets Endpoints Living Cell Technologies Advancing Regenerative Cell Therapy into Larger Phase IIb Study to Evaluate Its Potential as a Disease-modifying Treatment More >>
LCT completes patient implants in Parkinson’s trial
Monday, 15 December 2014, 12:38 pm | Living Cell Technologies
Living Cell Technologies Limited today announced that the final patient has been successfully implanted in its Phase I/IIa clinical trial of regenerative cell therapy NTCELL® for Parkinson’s disease. The operation took place at Auckland City Hospital ... More >>
LCT share purchase plan raises $1.08m
Thursday, 4 December 2014, 3:29 pm | Living Cell Technologies
Living Cell Technologies Limited today announced completion of its share purchase plan by the issue of 17,564,993 fully paid ordinary shares, raising an additional $1.08m. The shares will be allotted on 8 December 2014. More >>
LCT completes recruitment of patients in Parkinson’s trial
Monday, 3 November 2014, 12:19 pm | Living Cell Technologies
Living Cell Technologies Limited has completed recruitment of all patients for the Phase I/IIa clinical trial of the regenerative cell therapy NTCELL® for Parkinson’s disease. More >>
LCT JV secures funds to realise the potential of DIABECELL
Monday, 13 October 2014, 10:01 am | Living Cell Technologies
13 October 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (LCT) announced that its 50% owned joint venture Diatranz Otsuka Limited (DOL) has agreed to a loan facility of up to NZD42m from its other shareholder ... More >>
LCT announces completion of $3m placement and SPP
Wednesday, 8 October 2014, 12:34 pm | Living Cell Technologies
8 October 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced the placement of 49,410,392 fully paid Ordinary shares at $0.0608 to eligible persons resident in New Zealand, raising $3m. The issue ... More >>
LCT collaborates to develop novel neurological treatments
Monday, 29 September 2014, 5:15 pm | Living Cell Technologies
Living Cell Technologies Limited has formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCT’s lead product NTCELL®. More >>
LCT Appoints Scientific Advisors
Tuesday, 23 September 2014, 1:23 pm | Living Cell Technologies
Living Cell Technologies Limited (LCT) has appointed three high-level scientific advisors to review and support its work as NTCELL progresses towards commercialisation. The appointments are Professors Anne Young from Harvard, Roger Barker from Cambridge ... More >>
Successful second implant of NTCELL for Parkinson’s
Monday, 18 August 2014, 3:34 pm | Living Cell Technologies
18 August 2014 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® ... More >>
Dr Ken Taylor appointed Chief Executive
Tuesday, 8 July 2014, 1:19 pm | Living Cell Technologies
Living Cell Technologies Limited today announced that Dr Ken Taylor has been appointed Chief Executive. Ken was appointed NTCELL Program Director in February and became Acting Chief Executive in April. He has been successful resuming patient recruitment ... More >>
LCT Parkinson’s trial resumes patient recruitment
Monday, 23 June 2014, 1:00 pm | Living Cell Technologies
Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. More >>
